Search Bar & Filters
Found 30 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a study drug called LY4065967 for treating chronic low back pain CLBP. This trial is part of a larger master protocol aimed at speeding up the development of new treatments for chronic pain conditions. The study focuses on adults with a history of low back pain lasting at least three months. Participants will be randomly assigned to receive either LY4065967 or a placebo, both given orally. The study uses a double-blind design, meaning neither the participants nor the researchers know who receives the study drug or placebo. The treatment phase lasts for 8 weeks, during which participants take the assigned medication regularly. During the study, participants will be assessed at the start and at week 8 for changes in pain intensity using a numeric rating scale. Other evaluations include overall improvement, worst pain intensity, sleep quality, emotional functioning, use of rescue medication, and disability related to back pain. The trial includes safety monitoring and will continue until April 2027, with visits scheduled to track these outcomes.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the drug LY4065967 for treating diabetic peripheral neuropathic pain DPNP. This study is part of a larger chronic pain master protocol aimed at speeding up the development of new treatments for chronic pain conditions. Participants have diabetes and suffer from symmetrical nerve pain in their lower limbs. Participants will be randomly assigned to receive either LY4065967 or a placebo, both given orally. The study is double-blinded, meaning neither participants nor researchers know who receives which treatment. The treatment phase will last 8 weeks, during which pain and related symptoms will be monitored and compared between the groups. During the study, participants will have their pain intensity measured using a numeric rating scale at the start and at week 8. Other assessments include pain interference, overall improvement, sleep quality, emotional functioning, and daily use of rescue medication. The study involves regular monitoring to evaluate these outcomes and ensure participant safety throughout the 8-week treatment period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the drug LY4065967 for treating knee pain caused by osteoarthritis. This study is part of a larger effort called the chronic pain master protocol to speed up the development of new treatments for chronic pain conditions. The trial is a randomized, placebo-controlled Phase 2 study focusing on adults with knee osteoarthritis pain lasting more than 12 weeks. Participants will be randomly assigned to receive either LY4065967 or a placebo, both administered orally. The study compares these two groups to assess how well LY4065967 works in reducing knee pain and improving related symptoms. Treatment effects will be measured over an 8-week period, with evaluations at the start and end of this timeframe. During the study, participants will undergo regular assessments including pain intensity ratings using the Numeric Rating Scale, evaluations of arthritis symptoms, sleep quality, emotional functioning, and use of any rescue medication. Researchers will monitor the safety and effectiveness of the treatment through these measures. The total study duration for participants is approximately 8 weeks, with monitoring at baseline and week 8 to observe changes from the start of treatment.
Actively Recruiting
Researchers are conducting a master protocol study to evaluate multiple independent pain interventions for chronic pain conditions, including osteoarthritis of the knee, chronic low back pain, and diabetic peripheral neuropathic pain. This phase 2, randomized, placebo-controlled trial aims to establish a framework for disease-state addenda and intervention-specific appendices to efficiently study different treatments as they become available. Participants are randomly assigned to receive one of several investigational drugs or a matching placebo. These drugs include LY3016859 administered intravenously and LY3556050, LY3526318, LY3857210, and LY4065967 administered orally. Each intervention-specific appendix operates independently within the overarching study structure, allowing evaluation of various treatments targeting different chronic pain conditions. During the study, participants undergo screening and are monitored for pain levels using specific scales. They maintain consistent use of non-drug pain therapies and discontinue other chronic pain medications except rescue medication. Researchers measure participant allocation to each intervention up to week 8. Safety is monitored through physical exams, ECGs, laboratory tests, and medical history assessments. The study is expected to be completed by April 2027.
Actively Recruiting
Researchers are evaluating a new medication called VH4524184 for treating adults with HIV-1 who have never received treatment before. This Phase 2b study compares two doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide FTCTAF, against a standard HIV treatment combining dolutegravir and lamivudine DTG3TC. The goal is to collect long-term data on the antiviral activity of VH4524184 and to understand the best dosing for future studies. Participants are assigned to one of several groups one group receives a low dose of VH4524184 plus FTCTAF daily for 12 months, another group receives a high dose of VH4524184 plus FTCTAF daily for 12 months, and a third group takes DTG and 3TC daily for 24 months. After 12 months, those on VH4524184 may continue with a selected dose combined with FTCTAF daily until month 24. All medications are taken orally. During the study, participants attend scheduled visits for assessments including blood tests to measure HIV-1 RNA levels, CD4 T-cell counts, and drug concentrations. Researchers monitor the percentage of participants achieving viral suppression at 12 months and maintain it through 24 months. Safety is closely observed through tracking adverse events until roughly month 36. The total participation time may span up to 36 months to evaluate the long-term effects and safety of the treatments.
Actively Recruiting
Researchers are studying the safety and effectiveness of zenagamtide compared to semaglutide for treating adults with excess body weight. This Phase 3 trial focuses on participants with overweight or obesity to evaluate how these treatments help with weight loss. Participants are randomly assigned to one of three groups one receiving zenagamtide plus a placebo matching semaglutide, another receiving a lower dose of semaglutide plus a placebo matching zenagamtide, and the last group receiving a higher dose of semaglutide plus a placebo matching zenagamtide. All injections are given subcutaneously once weekly using pre-filled pen injectors in the thigh, abdomen, or upper arm. Participants also follow a reduced-calorie diet and increase physical activity throughout the study. During the 84-week study period, participants will be regularly monitored for changes in body weight and waist circumference. The main outcome is the relative change in body weight from the start to week 84. Safety and adherence will be assessed through scheduled visits where injections, diet, and exercise are reviewed. The study lasts until October 2028, with ongoing evaluations at specific intervals to understand treatment effects and safety.
Actively Recruiting
Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.
1-10 of 30
1